Stimulant withdrawal including amphetamines, methamphetamine or methcathinone (Q40429): Difference between revisions

@@ description / pt-br / description / pt-br @@
+Abstinência de estimulantes, incluindo anfetaminas, metanfetamina e metcatinona é um conjunto clinicamente significativo de sintomas, comportamentos e/ou manifestações fisiológicas, variando em grau de gravidade e duração, que ocorre quando da cessação ou redução do uso de estimulantes em indivíduos que tenham desenvolvido dependência de estimulantes ou tenham usado estimulantes por um período prolongado ou em grandes quantidades. A abstinência de estimulantes também pode ocorrer quando estimulantes prescritos foram usados em doses terapêuticas padrão. Sintomas de apresentação da abstinência de estimulantes podem incluir humor disfórico, irritabilidade, fadiga, insônia ou (mais comumente) hipersonia, sonhos vívidos e desagradáveis, aumento de apetite, agitação ou lentificação psicomotora, e fissura por anfetaminas ou estimulantes relacionados.
@@ description / en / description / en @@
+Stimulant withdrawal including amphetamines, methamphetamine and methcathinone is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of stimulants in individuals who have developed Stimulant dependence or have used stimulants for a prolonged period or in large amounts. Stimulant withdrawal can also occur when prescribed stimulants have been used in standard therapeutic doses. Presenting features of stimulant withdrawal may include dysphoric mood, irritability, fatigue, insomnia or (more commonly) hypersomnia, vivid and unpleasant dreams, increased appetite, psychomotor agitation or retardation, and craving for amphetamine or related stimulants.
@@ Property / Canonical URI @@
+https://id.who.int/icd/entity/494523519
@@ Property / Canonical URI: https://id.who.int/icd/entity/494523519 / rank @@
+Normal rank
@@ Property / CURIE @@
+CID11:6C46.4
@@ Property / CURIE: CID11:6C46.4 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-6C46.4
@@ Property / Canary Token: dki-india-6C46.4 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank
@@ Property / Linked ICD 10 @@
+F15.3
@@ Property / Linked ICD 10: F15.3 / rank @@
+Normal rank

Latest revision as of 06:14, 13 August 2026

Stimulant withdrawal including amphetamines, methamphetamine and methcathinone is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of stimulants in individuals who have developed Stimulant dependence or have used stimulants for a prolonged period or in large amounts. Stimulant withdrawal can also occur when prescribed stimulants have been used in standard therapeutic doses. Presenting features of stimulant withdrawal may include dysphoric mood, irritability, fatigue, insomnia or (more commonly) hypersomnia, vivid and unpleasant dreams, increased appetite, psychomotor agitation or retardation, and craving for amphetamine or related stimulants.

Language	Label	Description	Also known as
default for all languages	6C46.4
English	Stimulant withdrawal including amphetamines, methamphetamine or methcathinone	Stimulant withdrawal including amphetamines, methamphetamine and methcathinone is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of stimulants in individuals who have developed Stimulant dependence or have used stimulants for a prolonged period or in large amounts. Stimulant withdrawal can also occur when prescribed stimulants have been used in standard therapeutic doses. Presenting features of stimulant withdrawal may include dysphoric mood, irritability, fatigue, insomnia or (more commonly) hypersomnia, vivid and unpleasant dreams, increased appetite, psychomotor agitation or retardation, and craving for amphetamine or related stimulants.